➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Dow
Colorcon
Boehringer Ingelheim
Moodys
AstraZeneca

Last Updated: June 13, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR OZEMPIC

« Back to Dashboard

All Clinical Trials for Ozempic

Trial ID Title Status Sponsor Phase Start Date Summary
NCT03596450 Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial Recruiting Novo Nordisk A/S Phase 4 2018-07-13 The main purpose of this study is to compare the effects of semaglutide (Ozempic®) with the effects of other treatments for type 2 diabetes in a normal practice setting. The participant will be assigned by chance (like flipping a coin) to one of the following treatment groups: Group 1: semaglutide (Ozempic®) (by injection into skin) Group 2: standard of care antidiabetic medication (oral or injectable). The participant has an equal chance of being in either of the treatment groups. Neither the participant nor the study doctor or study staff will be able to pick which group the participant is in, but the participant will know which study drug the participant has been assigned to. The study doctor will provide the participant with a prescription for the study diabetes medication based on the treatment group the participant is assigned. The participation will last about 2 years.
NCT03724981 A Study Comparing the Dulaglutide Pen and the Semaglutide Pen Not yet recruiting Eli Lilly and Company Phase 4 2018-11-15 In this study participants will try out two different types of drug injection pens (dulaglutide and semaglutide) on a practice pad and decide which device they prefer. No study drug will be administered.
NCT03899402 Triple Therapy in T1DM Not yet recruiting University of Glasgow Phase 2/Phase 3 2019-05-01 To assess whether the addition of dapagliflozin to semaglutide and insulin (triple therapy) improves glycemic control in patients with type 1 diabetes compared with semaglutide and insulin (dual therapy) and insulin only (standard) treatment.
NCT03899402 Triple Therapy in T1DM Not yet recruiting State University of New York at Buffalo Phase 2/Phase 3 2019-05-01 To assess whether the addition of dapagliflozin to semaglutide and insulin (triple therapy) improves glycemic control in patients with type 1 diabetes compared with semaglutide and insulin (dual therapy) and insulin only (standard) treatment.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Ozempic

Condition Name

Condition Name for Ozempic
Intervention Trials
Type2 Diabetes 2
Obesity 2
Diabetes Mellitus, Type 2 2
Myocardial Injury 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Ozempic
Intervention Trials
Diabetes Mellitus 7
Diabetes Mellitus, Type 2 6
Puerperal Disorders 1
Dysgeusia 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Ozempic

Trials by Country

Trials by Country for Ozempic
Location Trials
United States 7
Canada 4
United Kingdom 2
Israel 1
Germany 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Ozempic
Location Trials
Ohio 2
Louisiana 1
South Carolina 1
New York 1
Maryland 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Ozempic

Clinical Trial Phase

Clinical Trial Phase for Ozempic
Clinical Trial Phase Trials
Phase 4 6
Phase 3 1
Phase 2/Phase 3 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Ozempic
Clinical Trial Phase Trials
Not yet recruiting 9
Recruiting 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Ozempic

Sponsor Name

Sponsor Name for Ozempic
Sponsor Trials
Novo Nordisk A/S 3
St. Michael's Hospital, Toronto 1
Medical University of South Carolina 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Ozempic
Sponsor Trials
Other 22
Industry 5
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Colorcon
McKesson
Baxter
Boehringer Ingelheim
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.